Urogen pharma ltd
URGN 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
URGN 近期報酬表現
-0.97%
Urogen pharma ltd
1.19%
同產業平均
0.91%
S&P500
與 URGN 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
UPC | Universe pharmaceuticals inc | 1 分 | 5 分 | 3 分 | - | 1 分 | |
ARMP | Armata pharmaceuticals inc | 5 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
EOLS | Evolus inc | 4 分 | 3 分 | 3 分 | 3 分 | 1 分 | |
TLRY | Tilray brands inc | 2 分 | 3 分 | 3 分 | 1 分 | 1 分 | |
GLTO | Galecto inc | 2 分 | 3 分 | 2 分 | 1 分 | 1 分 |
- UPC Universe pharmaceuticals inc價值 1 分趨勢 5 分波段 3 分籌碼 -股利 1 分查看更多
URGN 公司資訊
UroGen Pharma Ltd. Is an Israel-based biopharmaceutical company. The Company is engaged in building solutions for cancers and urologic diseases. UroGen has developed RTGelTM reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. Its lead product candidates include MitoGel and VesiGel are formulated using its proprietary reverse thermally triggered hydrogel, or RTGel, technology. MiroGel ( UGN-101) is a sustained release formulation of the chemotherapy agent Mitomycin C for the treatment of low-grade upper tract urothelial carcinoma, an urothelial cancer in the upper tract. VesiGel (UGN-102) is a sustained release formulation of a high dose Mitomycin C for the treatment of low grade non-muscle invasive bladder cancer (LG-NMIBC).